Zobrazeno 1 - 10
of 33
pro vyhledávání: '"Anna M. Hu"'
Autor:
Jamie N. Brown, Anna M. Hu
Publikováno v:
Clinical Rheumatology. 39:3287-3294
Patients with chronic kidney disease (CKD) are more likely to develop hyperuricemia and gout. Allopurinol and febuxostat are the most commonly used urate-lowering therapies with established safety and efficacy in CKD patients. The objective of the sy
Autor:
Anna M Hu, Marc J Pepin, Mohamed G Hashem, Rachel B Britt, Sara R Britnell, William E Bryan, Jamie N Brown
Publikováno v:
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 79(8)
Purpose To describe the development of a pilot specialty medication clinical dashboard targeting tumor necrosis factor (TNF)-α inhibitor therapy. Summary This was a quality improvement project conducted between August 2019 and April 2020. The dashbo
Autor:
Anna M, Hu, Jamie N, Brown
Publikováno v:
Clinical rheumatology. 39(11)
Patients with chronic kidney disease (CKD) are more likely to develop hyperuricemia and gout. Allopurinol and febuxostat are the most commonly used urate-lowering therapies with established safety and efficacy in CKD patients. The objective of the sy
Publikováno v:
Central Pacific Financial Corporation MarketLine Company Profile. 5/1/2024, p1-19. 19p.
Publikováno v:
American Journal of Health-System Pharmacy. Dec2022, Vol. 79 Issue 24, p2307-2312. 6p.
Publikováno v:
Central Pacific Financial Corporation MarketLine Company Profile. 4/14/2023, p1-17. 17p.
Autor:
Hu, Anna M1,2 anna.hu@memorialhermann.org, Pepin, Marc J3, Hashem, Mohamed G1, Britt, Rachel B1, Britnell, Sara R1, Bryan, William E3, Brown, Jamie N1
Publikováno v:
American Journal of Health-System Pharmacy. 4/15/2022, Vol. 79 Issue 8, p683-688. 6p. 3 Charts.
Publikováno v:
Fair Disclosure Wire (Quarterly Earnings Reports). 07/29/2020.
Publikováno v:
Fair Disclosure Wire (Quarterly Earnings Reports). 10/25/2023.
Autor:
Hu, Anna M., Brown, Jamie N.
Publikováno v:
Clinical Rheumatology; Nov2020, Vol. 39 Issue 11, p3287-3294, 8p